Can Test Reports from Other Countries Be Reused for US FDA Medical Device Registration?

Can Test Reports from Other Countries Be Reused for US FDA Medical Device Registration?

When registering a medical device with the US FDA, companies often wonder if test reports already completed in China (e.g., NMPA type-test reports), the EU (CE test reports), or other countries can be directly submitted to the FDA. The answer is that it depends on the situation: the FDA does not directly recognize reports from non-FDA-laboratories; however, if the tests are based on international standards (e.g., IEC 60601, ISO 10993) and the laboratory holds ISO 17025 accreditation, the reports may be used as supporting technical documentation to reduce redundant testing costs.

Applicable Scenarios and Core Issues

In US FDA registration, companies often wish to reuse test reports obtained from NMPA in China, EU CE marking, or other markets to save time and cost. The core question is whether the FDA directly accepts these reports. The answer is no, but if the reports meet specific conditions, they can serve as supporting evidence. Applicable scenarios include products that have completed registration in China with NMPA type-test reports, products with CE certificates and EN test reports, or products tested in other markets (e.g., Japan, Brazil, Australia). These reports, if covering electrical safety, electromagnetic compatibility, biocompatibility, or performance verification, may theoretically be reusable. However, the FDA has specific requirements for test laboratory qualifications (typically ISO 17025 accreditation) and test standards must comply with FDA-recognized consensus standards (e.g., ANSI/AAMI, IEC version differences). Companies must assess report acceptability in advance to avoid deficiencies or retesting, which could delay registration by 3–12 months.

Registration Decision Logic

Step 1: Determine Product Classification

Confirm whether the product falls under FDA medical device regulation, considering special rules for software, accessories, IVDs, or combination products.

Step 2: Identify Product Class and Submission Pathway

Determine the product class (Class I/II/III) and the registration pathway (510(k), PMA, De Novo, or exemption). Different pathways have varying levels of scrutiny for test reports. For example, 510(k) requires demonstration of substantial equivalence, with test reports focusing on performance comparison; PMA requires complete preclinical and clinical data, and test reports are only part of the evidence.

Step 3: Compare Existing Reports Against FDA Guidelines

Compare each existing test report against FDA guidance documents. Key points: whether the test standard is the latest version (e.g., FDA adoption of IEC 60601-1 3.1 Edition vs. 4th Edition); whether the laboratory has ISO 17070 or equivalent accreditation; whether any test items are missing (e.g., UL 60601-1 difference tests, cybersecurity tests, usability engineering).

Step 4: Assess Evidence Completeness

When reusing reports, provide the original report, test equipment calibration records, sample description, and test conditions. Attach declarations such as a standard gap analysis or laboratory qualification exemption statement.

Step 5: Confirm Local Agent and Post-Market Requirements

Even if test reports are accepted, companies must designate a US agent, establish a quality system (QSR 820), and submit adverse event reports.

Documents and Evidence for Reusable Reports

Reusable test reports should include: 1) the original test report (bilingual or English translation); 2) laboratory accreditation certificate (e.g., ISO 17025); 3) a standard gap analysis table comparing test standard versions with FDA requirements; 4) a sample consistency statement declaring that the tested sample matches the intended registration sample; and 5) if necessary, supplementary test reports (e.g., for FDA-specific requirements).

For biocompatibility reports (ISO 10993 series), the FDA typically requires GLP or equivalent quality system, and reports should include material characterization, cytotoxicity, sensitization, and irritation. If the original report does not cover additional FDA requirements (e.g., hemocompatibility, implantation local effects), supplementary testing is needed.

For electrical safety reports (IEC 60601-1), key reuse considerations: version differences (FDA currently accepts 3.1 Edition, but 4th Edition is available); FDA-specific deviations such as leakage current limits, accessible part temperature rise, and mechanical hazards.

For EMC reports (IEC 60601-1-2), confirm whether emission and immunity limits meet FDA requirements (e.g., CISPR 11 vs. FCC Part 18 differences).

Common Mistakes

• Mistake 1: Directly submitting NMPA type-test reports without translation or laboratory accreditation evidence.
• Mistake 2: Ignoring FDA-specific test standard version requirements, e.g., assuming CE EN 60601-1 3rd Edition satisfies FDA.
• Mistake 3: Biocompatibility reports lacking material characterization or relying solely on supplier data without actual testing.
• Mistake 4: Cybersecurity testing missing or based only on general architecture descriptions without threat modeling and vulnerability assessment per FDA guidance.
• Mistake 5: Submitting applications without designating a US agent, leading to document rejection.
• Mistake 6: Reusing test reports without a standard gap analysis, leaving FDA reviewers unable to assess compliance.

Company Preparation Checklist

• Determine product FDA classification and regulatory pathway; review relevant guidance documents.
• Collect all existing test reports and compare each against the FDA-recognized standards list.
• Verify laboratory accreditation (ISO 17025 certificate, GLP statement) is current.
• Prepare a standard gap analysis report clarifying the version alignment for each test item.
• Prepare a sample consistency statement signed by the quality officer.
• Arrange supplementary testing for missing or differing items as needed.
• Designate a US agent and sign an agreement.
• Establish FDA QSR 820 quality system documentation, including design controls and CAPA.
• Develop a post-market surveillance plan (adverse event reporting, change notifications).
• Consult a professional regulatory consultant for a pre-submission review to avoid omissions.

AIMEILI Insights

We recommend that companies do not assume that tests passed in other countries will be accepted by the FDA. The most commonly misjudged aspects are laboratory qualification requirements and special test items (such as cybersecurity and usability). Early in the project, conduct a feasibility assessment of the reports, with regulatory experts comparing each item against FDA guidance to identify necessary supplementary tests. Reusable data typically includes basic electrical safety, EMC, and basic biocompatibility (cytotoxicity, sensitization, irritation), but version confirmation is essential.

Items that must be localized usually include: US-specific tests (e.g., UL 60601-1 differences), clinical evaluations accounting for US population differences, and labels and instructions that fully comply with FDA format. For multi-country registration strategies, we suggest unifying the technical file format, retaining original reports, and establishing a standard gap matrix for rapid conversion. The local agent is critical for certificate control and change maintenance: the FDA registration process requires a US agent for communication; certificate ownership belongs to the applicant, but agent changes can affect registration status.

During post-market maintenance, any label or process changes may require retesting or supplementary submissions. When reusing reports, consider traceability of changes.

Common Follow-Up Questions

What specific laboratory qualification does the FDA require?

The FDA generally requires laboratories to be ISO 17025 accredited, with the accreditation scope covering the standards tested. For specific tests (e.g., biocompatibility), the FDA also requires compliance with GLP (21 CFR Part 58). If a laboratory does not have ISO 17025 but can provide equivalent qualification proof (e.g., national metrology certification), it may be evaluated case by case, but with higher risk.

Can NMPA type-test reports be used directly for 510(k)?

No, they cannot be used as formal reports but may serve as supporting technical documents. They must be supplemented with laboratory accreditation evidence, a standard gap analysis, and assurance that the test standards are compatible with FDA requirements. For key performance parameters, the FDA may require repeat testing or third-party verification outside the Chinese laboratory.

Is sample reproduction needed when reusing reports?

No, but the tested sample must be consistent with the intended registration sample. If any design or material changes occur, the relevant test items must be retested. Companies should maintain detailed sample consistency statements and design change records.